Institution Directory

Clinical trials at Weill Cornell Medicine

Sites in New York, NY

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 3:31 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

779

Shown on this page

Current sort

Live official records

Conditions: Deep Vein Thrombosis, DVT
Interventions: Indigo Aspiration System; Device
Lead sponsor: Penumbra Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 229 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 42
States / cities: La Mesa, California • Long Beach, California • Los Angeles, California + 32 more

Conditions: Concussion, Mild
Interventions: Not listed
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 5 Years to 24 Years
Enrollment: 750 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 5
States / cities: Boston, Massachusetts • New York, New York • Syracuse, New York + 2 more

Conditions: Atopic Dermatitis, Eczema
Interventions: Digital App Mindfulness Meditation, Mindfulness Meditation Sheet; Behavioral
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 13 Years to 17 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 2
States / cities: New York, New York

Conditions: Rejection Acute Renal, Rejection Chronic Renal, Transplantation, Kidney Rejection Transplant
Interventions: Donor-derived cell-free DNA; Diagnostic Test
Lead sponsor: Paris Translational Research Center for Organ Transplantation; Other
Eligibility: Not listed
Enrollment: 5,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 14
States / cities: Los Angeles, California • Tampa, Florida • Atlanta, Georgia + 8 more

Conditions: Advanced Breast Carcinoma, Advanced Colon Carcinoma, Advanced Colorectal Carcinoma, Advanced Endometrial Carcinoma, Advanced Gastric Carcinoma, Advanced Gastroesophageal Junction Adenocarcinoma, Advanced Malignant Solid Neoplasm, Advanced Salivary Gland Carcinoma, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Gastric Cancer AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, HER2-Positive Breast Carcinoma, Malignant Hepatobiliary Neoplasm, Metastatic Breast Carcinoma, Metastatic Colon Carcinoma, Metastatic Colorectal Carcinoma, Metastatic Endometrial Carcinoma, Metastatic Gastric Carcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Salivary Gland Carcinoma, Stage III Colon Cancer AJCC v8, Stage III Colorectal Cancer AJCC v8, Stage III Major Salivary Gland Cancer AJCC v8, Stage III Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8, Stage IV Colon Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8, Stage IV Major Salivary Gland Cancer AJCC v8, Stage IV Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8, Unresectable Breast Carcinoma, Unresectable Colon Carcinoma, Unresectable Colorectal Carcinoma, Unresectable Endometrial Carcinoma, Unresectable Gastric Carcinoma, Unresectable Gastroesophageal Junction Adenocarcinoma, Unresectable Malignant Solid Neoplasm, Unresectable Salivary Gland Carcinoma
Interventions: Biopsy Procedure, Biospecimen Collection, Ceralasertib, Computed Tomography, Echocardiography Test, Multigated Acquisition Scan, Positron Emission Tomography, Trastuzumab Deruxtecan; Procedure · Drug · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 23
States / cities: Irvine, California • Los Angeles, California • Orange, California + 16 more

Conditions: Surgery-Complications, Anesthesia Complication, Anesthesia Awareness, Anesthesia, Surgery, Quality of Life, Pain, Postoperative, Anesthesia Morbidity
Interventions: Anesthetic technique Propofol TIVA, Anesthetic technique inhaled agent; Other
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 13,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 24
States / cities: Little Rock, Arkansas • San Francisco, California • Stanford, California + 18 more

Conditions: Lymphoma, Lymphoma, Non Hodgkin
Interventions: TLN-121, zeprumetostat (TLN-254); Drug
Lead sponsor: Treeline Biosciences, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 8
States / cities: Palo Alto, California • Grand Rapids, Michigan • St Louis, Missouri + 4 more

Conditions: Chronic Obstructive Pulmonary Disease (COPD), Allergies
Interventions: Omalizumab (Xolair®), Sodium Chloride (NaCl) 0.9 %; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 40 Years and older
Enrollment: 334 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 23
States / cities: Birmingham, Alabama • Tucson, Arizona • San Francisco, California + 16 more

Conditions: Non-Small Cell Lung Cancer
Interventions: Alectinib, Atezolizumab, Pemetrexed, Cisplatin, Carboplatin, Gemcitabine, Entrectinib, Cobimetinib, Vemurafenib, Bevacizumab, Divarasib, Docetaxel; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 12
States / cities: Sacramento, California • Denver, Colorado • Fort Myers, Florida + 9 more

Conditions: Breast Cancer
Interventions: Ovarian Function Suppression + Aromatase Inhibitor, Adjuvant Chemotherapy + Ovarian Function Suppression; Drug
Lead sponsor: NRG Oncology; Other
Eligibility: 18 Years to 60 Years · Female only
Enrollment: 3,960 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2034
U.S. locations: 1226
States / cities: Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 809 more

Conditions: Stage III Colon Cancer
Interventions: Signatera test, mFOLFOX6 3-6 month, CAPOX 3 month, mFOLFIRINOX, mFOLFOX6 6 month, CAPOX 6 month; Device · Drug
Lead sponsor: NRG Oncology; Other
Eligibility: 18 Years and older
Enrollment: 1,912 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2030
U.S. locations: 1037
States / cities: Birmingham, Alabama • Fairhope, Alabama • Mobile, Alabama + 723 more

Conditions: Central Sleep Apnea
Interventions: remede System; Device
Lead sponsor: Respicardia, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 225 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2030
U.S. locations: 29
States / cities: Phoenix, Arizona • Scottsdale, Arizona • San Francisco, California + 24 more

About this Weill Cornell Medicine institution page

What this page lists: ClinicalTrials.gov records that list Weill Cornell Medicine in New York, NY as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status: A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Clinical trials at Weill Cornell Medicine

Filter and sort this campus

Live official records

BOLT-DVT: Study of the Indigo® Aspiration System When Used in Patients With Deep Vein Thrombosis

Poly-omic Predictors of Symptom Duration and Recovery for Adolescent Concussion

Digital Mindfulness Meditation in Adolescents With Atopic Dermatitis

Extended Validation of Donor-derived Cell-free DNA in Kidney Transplant Recipients

Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial

Trajectories of Recovery After Intravenous Propofol Versus Inhaled VolatilE Anesthesia Trial

TLN-121 in Relapsed or Refractory Non-Hodgkin Lymphomas

Clinical Trial of Omalizumab for Allergen Sensitized and Exposed Individuals With COPD

A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)

Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease

remedē System Therapy Study

About this Weill Cornell Medicine institution page